GSK plc

BRSE:001102657 Stock Report

Market Cap: CHF 81.6b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

GSK Valuation

Is 001102657 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 001102657 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
CHF 77.95
Fair Value
66.5% undervalued intrinsic discount
20
Number of Analysts

Below Fair Value: 001102657 (CHF26.12) is trading below our estimate of fair value (CHF77.95)

Significantly Below Fair Value: 001102657 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 001102657?

Key metric: As 001102657 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 001102657. This is calculated by dividing 001102657's market cap by their current earnings.
What is 001102657's PE Ratio?
PE Ratio13.8x
EarningsUK£5.11b
Market CapUK£70.58b

Price to Earnings Ratio vs Peers

How does 001102657's PE Ratio compare to its peers?

The above table shows the PE ratio for 001102657 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average50.5x
NOVN Novartis
16.7x6.21%CHF 178.1b
ROG Roche Holding
24.8x13.92%CHF 207.0b
GALD Galderma Group
123.4x31.37%CHF 23.7b
DESN Dottikon ES Holding
37.2xn/aCHF 2.8b
001102657 GSK
13.8x8.91%CHF 70.6b

Price-To-Earnings vs Peers: 001102657 is good value based on its Price-To-Earnings Ratio (13.8x) compared to the peer average (35.3x).

Price to Earnings Ratio vs Industry

How does 001102657's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
001102657 13.8xIndustry Avg. 22.2xNo. of Companies10PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 001102657 is good value based on its Price-To-Earnings Ratio (13.8x) compared to the European Pharmaceuticals industry average (21.6x).

Price to Earnings Ratio vs Fair Ratio

What is 001102657's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

001102657 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.8x
Fair PE Ratio37.7x

Price-To-Earnings vs Fair Ratio: 001102657 is good value based on its Price-To-Earnings Ratio (13.8x) compared to the estimated Fair Price-To-Earnings Ratio (37.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 001102657 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
May ’26n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Apr ’26n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Mar ’26n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Feb ’26n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Jan ’26n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Dec ’25n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Nov ’25n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Oct ’25n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Sep ’25n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Aug ’25n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Jul ’25n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Jun ’25n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
May ’25n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Apr ’25n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Mar ’25n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Feb ’25n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Jan ’25n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Dec ’24n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Nov ’24n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Oct ’24n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Sep ’24n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Aug ’24n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Jul ’24n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
Jun ’24n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
May ’24n/a
CHF 26.30
0%
18.45%CHF 44.16CHF 17.80n/a20
AnalystConsensusTarget
Consensus Narrative from 20 Analysts
CHF 34.09
Fair Value
23.4% undervalued intrinsic discount
20
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/07/24 06:35
End of Day Share Price 2022/07/07 00:00
Earnings2022/03/31
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GSK plc is covered by 65 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamla SinghAlphaValue
John EadeArgus Research Company
Odile RundquistBaader Helvea Equity Research